Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2012/052649external-prioritypatent/WO2012164473A1/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of MA35155B1publicationCriticalpatent/MA35155B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Hydrogenated Pyridines
(AREA)
Abstract
L'invention concerne des dérivés représentés par la formule (i), dans laquelle les substituants sont tels que définis dans la spécification; des procédés de préparation de tels dérivés; des compositions pharmaceutiques comprenant de tels dérivés; ces dérivés utilisés comme médicament; de tels dérivés utilisés pour traiter un trouble ou une maladie induit(e) par le récepteur de la ghréline.The invention relates to derivatives represented by the formula (i), wherein the substituents are as defined in the specification; processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; these derivatives used as a medicine; such derivatives used to treat a disorder or disease induced by the ghrelin receptor.
MA36442A2011-05-272013-11-15
3-Spirocyclic Piperidine Derivatives as Ghrelin Receptor Agonists
MA35155B1
(en)
1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders